Sunday, May 22, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Findings of the HITCH randomized clinical trial show lack of improvement in COVID-19 on temporary androgen suppression

by Medical Finance
in Coronavirus
Study: Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19. Image Credit: StudioMolekuul/Shutterstock
9
SHARES
101
VIEWS
Share on FacebookShare on Twitter

In a recent study published in JAMA Network Open, researchers investigated whether temporary androgen suppression by degarelix improved the clinical outcomes among male patients hospitalized with coronavirus disease 2019 (COVID-19).

Study: Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19. Image Credit: StudioMolekuul/Shutterstock
Study: Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19. Image Credit: StudioMolekuul/Shutterstock

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires transmembrane serine protease 2 (TMPRSS2) for invading the host and replicating intracellularly. TMPRSS2 expression is regulated by androgen receptors (AR) and thus, anti-androgen therapies such as degarelix could potentially improve the clinical outcomes of COVID-19.

Degarelix is a luteinizing hormone (LH)-releasing hormone antagonist approved by the United States (US) Food and Drug Administration (FDA) for prostate cancer. It binds to the gonadotropin-releasing hormone receptors in the pituitary gland with an immediate onset and rapidly suppresses the secretion of LH and follicle-stimulating hormone (FSH), thereby reducing testosterone secretion within the testes and also decreasing the circulating androgen levels. This AR-targeted drug was chosen for the HITCH (hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization) trial due to its rapid action, safety profile, availability, and reversibility.

About the study

In the present study, researchers assessed the improvement in clinical outcomes among males hospitalized with COVID-19 by temporarily suppressing their androgen levels using degarelix. The authors of the present study have summarized the findings of the HITCH trial, a multicenter, phase II, double-blinded randomized clinical trial.

The HITCH trial was conducted at 14 Veterans Affairs (VA) medical centers and comprised 96 male COVID-19 patients after the post-interim analysis (initially 198 patients) recruited between July 22, 2020, and April 8, 2021. The participants, aged above 18 years, with reverse transcription-polymerase chain reaction (RT-PCR)-confirmed COVID-19 were stratified by age, hypertension history, and COVID-19 severity and randomized in a 2:1 ratio to receive either degarelix (one 240 mg dose administered subcutaneously, n=62) or a placebo (saline, n=34) with the standard of care treatment (antibiotics, remdesivir, dexamethasone, vasopressors, oxygen supplementation, hemodialysis or peritoneal dialysis, intravenous (i.v.) fluids, and convalescent plasma).

An electrocardiogram (ECG) was used during screening for excluding patients with corrected QT interval prolongation at baseline. Laboratory assessments for evaluating drug safety were performed at the local VA laboratories and included routine complete blood counts, hepatic function, blood chemistry, cardiovascular function, and inflammatory markers. Total serum testosterone was measured during screening and, on days 8, 15, and 30. Adverse events (AEs) were assessed every day during hospitalization, and post-discharge, on days 30 and 60.

The primary composite primary endpoint comprised ongoing hospitalization, mechanical ventilation requirements, and mortality at 15 days post-randomization. The secondary composite endpoint comprised the time required for improvement in clinical variables or hospital discharge, inpatient mortality, duration of hospitalization, duration of intubation for mechanical ventilation, the time required to attain reference range temperatures, and maximum COVID-19 severity at 30 days post-randomization.

Data analysis was performed between August 9 and October 15, 2021. The adjusted odds ratios (aOR) were calculated to compare the efficacy of androgen suppression in the study cohort.

Results

In the HITCH randomized clinical trial, androgen suppression induced by degarelix compared to placebo with standard care did not reduce the composite endpoint of current hospitalization, mortality, or mechanical ventilation requirements 15 days post-randomization.

The mean age of the patients was 70.5 years. The most common comorbidities in the patients were hypertension (78%), diabetes (51%), cardiovascular diseases (28%), chronic obstructive pulmonary disorder (15.6%), asthma (12.5%), and chronic respiratory failure requiring supplemental oxygen at baseline prior to COVID-19 (9.4%).

For the primary composite endpoint, no significant differences were observed between the two groups. After 15 days of randomization, 19 patients (31%) and nine patients (27%) in the degarelix group and the placebo group, respectively, either continued to be hospitalized, died, or needed mechanical ventilation (aOR 1.2; P = 0.7).

For the secondary composite endpoint, after 30 days of randomization, the ongoing hospitalization, mechanical ventilation requirements, or mortality were observed among 15 patients (24%) and seven patients (21%) in the degarelix and placebo groups, respectively (aOR, 1.2; P = 0.69). Additionally, 11 patients (17.7%) and six patients (17.6%) in the degarelix and placebo groups died prior to discharge, respectively (aOR, 0.95; P = 0.99, with one additional death in the placebo group post-discharge. Maximum COVID-19 severity did not differ among the two groups (aOR, 0.8; P = 0.4).

The mean duration of hospital stay was six days and five days for the degarelix and the placebo groups, respectively (P = 0.8). No significant difference was observed in the time required to attain reference range temperatures between the two groups. Among the patients admitted to the hospital on day 8, the mean serum testosterone levels were 40 ng/dL and 130 ng/dL in the degarelix and the placebo groups, respectively.

No significant differences were observed among patients in the degarelix and placebo groups for overall AEs [13 patients (21%) vs eight patients (24%)] or serious AEs [19 patients (31%) vs 13 patients (32%)]. Additionally, no significant differences were observed for cardiovascular AEs between the two groups [two patients (3%) vs three patients (9%)].

Overall, the study findings showed that in the HITCH clinical trial, suppressing androgen did not ameliorate COVID-19 severity.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: High prevalence of olfactory disorders 18 months after contracting COVID-19. Image Credit: Nenad Cavoski/Shutterstock

Prevalence of olfactory dysfunction 18 months after SARS-CoV-2 infection

by Medical Finance
May 22, 2022
0

To date, 351 million individuals have been infected by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causal agent of...

Study: SARS-CoV-2 Omicron BA.1 variant infection of human colon epithelial cells. Image Credit: PHOTOCREO Michal Bednarek/Shutterstock

Study explores SARS-CoV-2 Omicron variant and infected colon epithelial cells

by Medical Finance
May 22, 2022
0

In a recent study posted to the bioRxiv* preprint server, researchers assessed the impact of the severe acute respiratory syndrome...

Study: Social Distancing Causally Impacts The Spread of SARS-CoV-2: A U.S. Nationwide Event Study. Image Credit: oatawa/Shutterstock

Causal impact of spontaneous relaxation of social distancing practices on spread of SARS-CoV-2 in US

by Medical Finance
May 22, 2022
0

The highly contagious novel coronavirus caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which emerged in December 2019 in...

Study: Humoral Response to The Third Dose Of SARS-Cov-2 Vaccine in Kidney Transplant Recipients. Image Credit: bluebay / Shutterstock.com

Third dose of COVID mRNA vaccine safe and effective in kidney transplant patients

by Medical Finance
May 22, 2022
0

Immunocompromised patients are at a high risk of severe coronavirus disease 2019 (COVID-19) and also respond poorly to vaccination with...

Study: Estimating the risk of hospitalisation and death in England

The impact of COVID-19 vaccine hesitancy and resistance on the population of England

by Medical Finance
May 22, 2022
0

A study conducted by the UK Health Security Agency has recently estimated the rate of hospitalization and death due to...

Study: T cell response following anti COVID-19 BNT162b2 vaccination is maintained against the SARS-CoV-2 Omicron B.1.1.529 variant of concern. Image Credit: natatravel/Shutterstock

Study finds stable T-Cell response against Omicron after mRNA booster vaccination

by Medical Finance
May 22, 2022
0

 Antibodies are critical when talking about protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated variants. However,...

Next Post
Study: T-cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals

Booster vaccines found to augment T-cell responses to SARS-CoV-2 Omicron

Study: USP22 controls type III interferon signaling and SARS-CoV-2 infection through activation of STING. Image Credit: Juan Gaertner / Shutterstock

USP22 crucial for type III interferon signaling and SARS-CoV-2 infection

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Homogeneity of sample distribution compared between contact pin spotter (left) and Arrayjet printer (right).
    Cost-effective and reproducible cell-free arrays
  • Potatoes with peel isolated on white background Domnitsky 0ac06561439540adb685089bd0bad202 620x480
    Microbes in animals’ guts influence diet selection behavior, research shows
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply